Observational studyNeurosurgical review2025
Evaluation of clinical outcome and predictive factors for thromboembolism or hemorrhagic complications in patients treated for chronic subdural hematoma. A prospective observational study.
Observational study in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The impact of anticoagulant and antiplatelet medications on clinical outcome and risk of complications is uncertain in chronic subdural hematoma (CSDH) patients. Currently, evidence-based guidelines and specific neurosurgical scores lacks. CHA₂DS₂-VASc and HAS-BLED scores have been proven to help predicting complications in the perioperative period of non-cardiac surgeries. We performed a multicenter prospective observational trial to evaluate the clinical outcomes and complications of CSDH patient undergoing surgery, comparing patients taking anticoagulant/antiplatelet (AAPT) and not (NT). Additionally, we investigated the role of CHA₂DS₂-VASc and HAS-BLED scores in predicting thromboembolic events or hemorrhages. No associations have been found between AAPT and clinical outcomes of patients. Emergency surgery was not a significant factor in improving outcomes. Post-operative hemorrhages were more frequent in the AAPT group, but none required a second surgery. A significant higher risk of of new bleedings was found in the ASA group with discontinuation ≤ 5 days. A higher HAS-BLED score was not associated with a worse clinical outcome. A 1-point increase in CHA₂DS₂-VASc was associated with a lower probability of favorable outcomes at 1 month. 90% of AAPT and 44% of NT patients were at moderate-high risk of thromboembolic events based on CHA₂DS₂-VASc score, with no difference in incidence between groups. The use of AAPT does not influence outcomes, complication rates, or recurrence in patients undergoing surgery for CSDH. Scores such as CHA₂DS₂-VASc or HAS-BLED could aid in stratifying bleeding and thromboembolic risks and in the management of these drugs in the perioperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.